Who Paid My Doc
Phillip Scheinberg
Hematology & Oncology Bethesda, MD Medical Doctor
NPI 1164748133 CMS profile 681490
10 Center Dr, Bldg 10 Crc, Rm 3-5140, Bethesda, MD 20892
General payments
$26,992
Research payments
$20,849
Ownership & investment interest
$0
Research they led as principal investigator
$350
Through program year 2025, Phillip Scheinberg of Bethesda, MD is reported in the CMS Open Payments database as having received $26,992 across 26 general payments and $20,849 in research payments paid to them. Separately, studies naming them as principal investigator received $350 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $87 | 1 | |
| 2025 | Research | $2,327 | 2 | |
| 2024 | General | $2,072 | 2 | |
| 2024 | Research | $3,822 | 1 | |
| 2023 | Research | $3,884 | 1 | |
| 2022 | General | $4,297 | 7 | |
| 2022 | Research | $543 | 2 | |
| 2021 | Research | $3,352 | 4 | |
| 2020 | General | $8,309 | 4 | |
| 2020 | Research | $4,375 | 2 | |
| 2019 | General | $12,227 | 12 | |
| 2019 | Research | $2,546 | 3 |
Beside peers
- Phillip Scheinberg
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Phillip Scheinberg were reported at $87. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Phillip Scheinberg | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12,227 | $529 | $121–$2,516 | $163 |
| 2020 | $8,309 | $339 | $82–$2,213 | $114 |
| 2021 | $0 | $263 | $49–$1,965 | $132 |
| 2022 | $4,297 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $2,072 | $692 | $141–$3,008 | $164 |
| 2025 | $87 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
41 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Maryland
Ralph Boccia
Hematology & Oncology · Bethesda, MD
Sandra Swain
Hematology & Oncology · Bethesda, MD
Kashif Ali
Hematology & Oncology · Silver Spring, MD
Ani Balmanoukian
Hematology & Oncology · Baltimore, MD
Benjamin Levy
Hematology & Oncology · Baltimore, MD
Patrick Forde
Hematology & Oncology · Baltimore, MD
Related records
Hematology & Oncology in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.